| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2004-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_975b07cafdeeadf663ea40415f239020
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566a9a1843400f0dbd79dbe09067b616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e44f2b3463ce9b8407130aa718fb27e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74a5c863f32d0b7e9b91ab0cbced756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b294cd24df4ded8b0da4548ba42756ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eefee9bfcfd65f82668531f7cacf3a49 |
| publicationDate |
2009-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7553485-B2 |
| titleOfInvention |
Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| abstract |
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011091479-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011014117-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008193445-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8101180-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7914784-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011091524-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7854930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008286198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011014122-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8168410-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8470297-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8124079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013273031-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8420085-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009214525-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8852590-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011183376-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8808999-B2 |
| priorityDate |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |